21227 ⎘
Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
VACCINATION IN NEWBORNS AND INFANTS
#2VACCINATION IN NEWBORNS AND INFANTS
#3HENIPAVIRUS VACCINE
#4PEPTIDE CONJUGATED PARTICLES
#5VACCINATION IN ELDERLY PATIENTS
#6Composition for Oral or Nasal Delivery of Tetanus, Diphtheria, and Pertussis Vaccine alone or in combination using Neurotoxin Associated Proteins
#7Vaccination with mRNA-coded antigens
#8COMPLEXES FOR DELIVERY OF ANTIGENIC PEPTIDES
#9Composition for oral or nasal delivery of tetanus, diphtheria, and pertussis vaccine alone or in combination using neurotoxin associated proteins
#10Methods for Enhancing Efficacy of a Vaccine by Administering an IL-4R Antagonist
#11VACCINATION IN NEWBORNS AND INFANTS
#12Henipavirus vaccine
#13Sustained release cowpea mosaic virus or virus-like particle therapeutic constructs for the treatment of cancer
#14PRODUCTION OF MHC II/CII COMPLEXES
#15Heat Shock Protein-Binding Peptide Compositions And Methods Of Use Thereof
#16PEPTIDE CONJUGATED PARTICLES
#17Peptide conjugated particles
#18Controlled release vaccines and methods of treating diseases and disorders
#19Sustained release cowpea mosaic virus or virus-like particle therapeutic constructs for the treatment of cancer
#20MODULAR ANTIGEN TRANSPORTATION MOLECULES AND USES THEREOF IN ANIMALS
#21VACCINATION IN NEWBORNS AND INFANTS
#22VACCINATION WITH mRNA-CODED ANTIGENS
#23Comprehensive vaccine design for commensal disease progression
#24Vaccination in newborns and infants
#25Peptide conjugated particles
#26Complexes for delivery of antigenic peptides
#27Heat shock protein-binding peptide compositions and methods of use thereof
#28Henipavirus vaccine
#29Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
#30Vaccination in newborns and infants
#31VACCINATION WITH mRNA-CODED ANTIGENS
#32Controlled release vaccines and methods for treating diseases and disorders
#33Composition for oral or nasal delivery of tetanus, diphtheria, and pertussis vaccine alone or in combination using neurotoxin associated proteins
#34Vaccination in newborns and infants
#35Compositions and methods for stabilization of active agents
#36ANTI-HLA ASSAY AND METHODS
#37Peptide conjugated particles
#38Carrier molecule compositions and related methods
#39Use of liposomes in a carrier comprising a continuous hydrophobic phase as a vehicle for cancer treatment
#40Protective antigen complexes with increased stability and uses thereof
#41Her2/neu immunogenic composition
#42ANTAGONIST ANTIBODIES AGAINST GDF-8 AND USES THEREFOR
#43Peptide conjugated particles
#44COMPOSITIONS AND METHODS FOR STABILIZATION OF ACTIVE AGENTS
#45Peptide conjugated particles
#46Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
#47Methods for enhancing efficacy of a vaccine by administering an IL-4R antagonist
#48CARBOHYDRATE FUNCTIONALIZED CATANIONIC SURFACTANT VESICLES FOR DRUG DELIVERY
#49Vaccination in newborns and infants
#50Vaccination with mRNA-coded antigens
#51Immunostimulatory nanocomplex
#52Modular antigen transportation molecules and uses thereof in animals
#53Antigen and method for production thereof
#54VACCINATION IN ELDERLY PATIENTS
#55Controlled release vaccines and methods of treating diseases and disorders
#56Delivery of self-replicating RNA using biodegradable polymer particles
#57Antagonist antibodies against GDF-8 and uses therefor
#58Nasal vaccine against the development of atherosclerosis disease and fatty liver
#59Synthetic membrane-receiver complexes
#60Peptide conjugated particles
#61Composition comprising cytokine macro-aggregates
#62Use of liposomes in a carrier comprising a continuous hydrophobic phase as a vehicle for cancer treatment
#63Peptide conjugated particles
#64Nanocarriers with multi-photon response elements
#65Stable Anthrax Vaccine Formulations
#66Methods of administering immunosuppressants having a specified pharmacodynamic effective life and therapeutic macromolecules for the induction of immune tolerance
#67Tolerogenic synthetic nanocarriers to reduce or prevent anaphylaxis in response to a non-allergenic antigen
#68COMPOSITIONS AND METHODS FOR STABILIZATION OF ACTIVE AGENTS
#69Bovine virus vaccines that are liquid stable
#70Controlled release vaccines and methods for treating diseases and disorders
#71Process for preparing vaccine composition
#72Immunogens for treatment of neoplastic and infectious disease
#73EPITOPE TESTING USING SOLUBLE HLA
#74ANTI-HLA ASSAY AND METHODS
#75COMPARATIVE LIGAND MAPPING FROM MHC CLASS I POSITIVE CELLS
#76COMPARATIVE LIGAND MAPPING FROM MHC POSITIVE CELLS
#77Nanocarriers with multi-photon response elements
#78Immunogenic compositions containing phospholipid
#79Stable immunogenic product comprising antigenic heterocomplexes
#80Stable anthrax vaccine formulations
#81CARBOHYDRATE FUNCTIONALIZED CATANIONIC SURFACTANT VESICLES FOR DRUG DELIVERY
#82EPITOPE TESTING USING SOLUBLE HLA
#83Method of transfection and compositions therefor
#84High Molecular Weight Amyloid Beta As a Carrier for the Oral Delivery of Vaccine Antigens
#85CONSTRAINED HIV ENVELOPE-BASED IMMUNOGEN THAT SIMULTANEOUSLY PRESENTS RECEPTOR AND CORECEPTOR BINDING SITES
#86Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
#87Antigen conjugates and uses thereof
#88PURIFICATION AND CHARACTERIZATION OF SOLUBLE MHC PROTEINS
#89Use of Liposomes in a Carrier Comprising a Continuous Hydrophobic Phase as a Vehicle for Cancer Treatment
#90Bifunctional protein anchors
#91Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
#92COMPOSITION AND METHODS OF MAKING AND USING INFLUENZA PROTEINS
#93Methods for removing anti-MHC antibodies from a sample
#94Compositions and methods for using CA9 protein to stimulate an immune response
#95VACCINE COMPRISING AN ANTIGEN CONJUGATED TO LOW VALENCY ANTI-CD40 OR ANTI-CD28 ANTIBODIES
#96Isolated complexes of endotoxin and modified MD-2
#97Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
#98Hiv-1 Neutralizing Antibodies Elicited By Trimeric Hiv-1 Envelope Glycoprotein Complex
#99Heat shock protein-based vaccines and immunotherapies
#100Cancer Vaccine Preparation
#101Expression of HLA proteins on non human cells
#102Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
#103Recombinant cancer cell secreting modified heat shock protein-antigenic peptide complex
#104Comparative ligand mapping from MHC positive cells
#105Purification and characterization of soluble human HLA proteins
#106Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins
#107Vaccine comprising an antigen conjugated to low valency anti-cd40 or anti-cd28 antibodies
#108Stable immunogenic product comprising antigenic heterocomplexes
#109Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
#110Epitope testing using soluble HLA
#111Soluble MHC artificial antigen presenting cells
#112Method for preparing a stable TNF-α vaccine
#113Heat shock protein-based vaccines and immunotherapies
#114Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
#115Heat shock protein-based vaccines and immunotherapies
#116Method and composition
#117Methods for recovering peptides from stress protein-peptide complexes
#118Human immunodeficiency virus envelope clycoprotein mutants and uses thereof
#119Method for inducing cytotoxic T lymphocyte
#120Methods of attaching soluble HLA to solid supports
#121Comparative ligand mapping from MHC class 1 positive cells